Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Biological anti-TNF drugs: immunogenicity underlying treatment failure and adverse events

Publikation: Bidrag til tidsskriftReviewForskningpeer review

  1. Review of dose-response curves for acute antimigraine drugs: triptans, 5-HT1F agonists and CGRP antagonists

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Albiglutide for treating type 2 diabetes: an evaluation of pharmacokinetics/pharmacodynamics and clinical efficacy

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Sumatriptan: a review of its pharmacokinetics, pharmacodynamics and efficacy in the acute treatment of migraine

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Pharmacokinetic evaluation of pemetrexed

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Therapeutic thresholds and mechanisms for primary non-response to infliximab in inflammatory bowel disease

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Personalized medicine in rheumatoid arthritis: How immunogenicity impacts use of TNF inhibitors

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Pattern recognition receptor polymorphisms in early periodontitis

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Lewis and AB0 blood group-phenotypes in periodontitis, cardiovascular disease, obesity and stroke

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

INTRODUCTION: Genetically engineered monoclonal antibodies and fusion proteins directed against cytokines or their receptors represent a breakthrough in the treatment of various chronic immune-inflammatory diseases. Areas covered: Studies show high remission rates in several diseases, but clinical practice shows a significant percentage of individuals who do not exhibit the desired response. Loss of therapeutic benefit after initial successful response is designated secondary failure. Immune-biological agents are not self-antigens and are therefore potentially immunogenic. Secondary failure is frequently caused by antibodies against immune-biologicals, known as anti-drug antibodies (ADA). ADA that neutralize circulating immune-biologicals and/or promote their clearance can reduce treatment efficacy. Furthermore, ADA can induce adverse events by diverse immunological mechanisms. This review provides a comprehensive overview of ADA in rheumatoid arthritis patients treated with anti-TNF immune-biologicals, and explores the concept of therapeutic drug monitoring (TDM) as an effective strategy to improve therapeutic management. Expert opinion: Monitoring circulating ADA and therapeutic immune-biological drugs is helpful when evaluating patients with secondary failure. However, immunological tests for ADA vary considerably regarding their ability to detect different types of ADA. Several assays are not designed to determine ADA-induced drug neutralizing capacity, and they may report clinically non-relevant data, especially if drug is present in test samples.

OriginalsprogEngelsk
TidsskriftExpert Opinion on Drug Metabolism and Toxicology
Vol/bind13
Udgave nummer9
Sider (fra-til)985-995
Antal sider11
ISSN1742-5255
DOI
StatusUdgivet - sep. 2017

ID: 52406710